We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+24.43%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.3B
AUM Growth
-$343M
Cap. Flow
-$2.51B
Cap. Flow %
-18.9%
Top 10 Hldgs %
48.31%
Holding
117
New
19
Increased
28
Reduced
28
Closed
22

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$737M
2
SPGI icon
S&P Global
SPGI
+$177M
3
SHW icon
Sherwin-Williams
SHW
+$160M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$145M
5
GG
Goldcorp Inc
GG
+$139M

Top Sells

Rank Stock Value
1
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
+$616M
2
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
+$370M
3
EQIX icon
Equinix
EQIX
+$283M
4
META icon
Meta Platforms (Facebook)
META
+$194M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$193M

Sector Composition

Rank Sector Weight
1 Healthcare 29.51%
2 Technology 21.38%
3 Communication Services 17.25%
4 Industrials 6.59%
5 Consumer Discretionary 6.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SE icon
26
Sea Limited
SE
$72B
$163M 1.22%
+6,920,000
New +$121M
AZN icon
27
AstraZeneca
AZN
$257B
$157M 1.18%
1,942,500
– –
CI icon
28
Cigna
CI
$73.3B
$152M 1.14%
945,000
-110,000
-10% -$20.1M
WCG
29
DELISTED
Wellcare Health Plans, Inc.
WCG
$151M 1.14%
+560,000
New +$145M
GG
30
DELISTED
Goldcorp Inc
GG
$148M 1.12%
+12,960,000
New +$139M
ARRY
31
DELISTED
Array Biopharma Inc
ARRY
$134M 1.01%
5,500,000
-250,000
-4% -$5.2M
ARRS
32
DELISTED
ARRIS International plc Ordinary Shares
ARRS
$118M 0.89%
3,745,000
+165,000
+5% +$5.17M
ZGNX
33
DELISTED
Zogenix, Inc.
ZGNX
$113M 0.85%
2,050,500
– –
XLRN
34
DELISTED
Acceleron Pharma
XLRN
$111M 0.83%
2,375,000
+275,000
+13% +$12.1M
LBTYK icon
35
Liberty Global Class C
LBTYK
$3.55B
$104M 0.78%
4,308,106
-629,096
-13% -$14.9M
MYOK
36
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$101M 0.76%
1,950,278
+350,000
+22% +$16.1M
FOX icon
37
Fox Class B
FOX
$25.6B
$101M 0.76%
+2,807,431
New +$107M
LBTYA icon
38
Liberty Global Class A
LBTYA
$3.63B
$98.4M 0.74%
3,949,553
-2,022,884
-34% -$49.4M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$95.4M 0.72%
600,000
+200,000
+50% +$29M
ONCE
40
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$93.4M 0.7%
+820,000
New +$60.3M
ENTA icon
41
Enanta Pharmaceuticals
ENTA
$392M
$89.8M 0.68%
940,000
+15,000
+2% +$1.35M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$88M 0.66%
1,200,000
-100,000
-8% -$6.8M
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
$79.4M 0.6%
1,500,000
+50,000
+3% +$2.46M
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.98B
$77.5M 0.58%
650,000
+10,000
+2% +$1.29M
BABA icon
45
Alibaba
BABA
$286B
$75.7M 0.57%
415,000
-635,000
-60% -$107M
EXEL icon
46
Exelixis
EXEL
$13.4B
$71.4M 0.54%
3,000,000
+1,000,000
+50% +$22.8M
AMRN
47
Amarin Corp
AMRN
$298M
$67.5M 0.51%
162,500
-12,500
-7% -$4.51M
RETA
48
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$64.1M 0.48%
750,000
+50,000
+7% +$4.15M
GRFS
49
Grifois
GRFS
$5.44B
$58.8M 0.44%
2,926,352
+545,233
+23% +$10.4M
IOVA icon
50
Iovance Biotherapeutics
IOVA
$3.76B
$54.4M 0.41%
5,725,000
– –
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2019 Portfolio in Review

As of Q1 2019, Thomas Steyer held 117 positions worth $13.3B, down 2.5% from $13.6B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Thomas Steyer withdrew a net $2.51B in Q1 2019, closing 22 positions and reducing 28 holdings. Its most notable exit was Twenty-First Century Fox, Inc. Class A, an estimated $616M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 21% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Thomas Steyer opened a new position in Celgene Corp worth $795M.

  • Thomas Steyer's largest Q1 2019 buy was Celgene Corp: 8,430,000 shares worth $795M.
  • Thomas Steyer added most to Red Hat Inc in Q1 2019, an estimated $116M increase.
  • Thomas Steyer's biggest Q1 2019 reduction was Equinix, cutting an estimated $283M.
  • Thomas Steyer fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $616M.
  • Thomas Steyer's ten largest holdings make up 48% of its $13.3B portfolio in Q1 2019.
  • Thomas Steyer opened 19 new positions and closed 22 in Q1 2019.
  • Thomas Steyer's portfolio value fell 2.5% quarter-over-quarter to $13.3B.

Based on Farallon Capital Management's 13F filing for Q1 2019, filed 15 May 2019.